Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 1050595Generated: October 31, 2026

Dimethylcarbamoyl Chloride → HCID 118115004, compound

https://huagongshe.com/reaction/1050595

Reaction equation

Participants

RoleNameHCIDCharge
ReactantDimethylcarbamoyl ChlorideHCID 6598—
ReactantDiisopropylethylamineHCID 81531—
Reactantrel-(4aR,8aR)-Decahydro-1,5-naphthyridineHCID 11083982—
Reactant3,5-Dichloropyrazine-2-carbonitrileHCID 52987744—
SolventEthyl AcetateHCID 8857—
SolventN-methyl-2-pyrrolidoneHCID 13387—
ProductHCID 118115004HCID 11811500419%

Reaction Steps

Commercial (4aR,8aR)-decahydro-1,5-naphthyridine (423, 120 mg, 0.86 mmol) was dissolved in 2 mL NMP. To it were added DIEA (150 μL, 0.86 mmol) and then 3,5-dichloropyrazine-2-carbonitrile (150 mg, 0.86 mmol). The mixture was stirred at RT for 1.5 hour, and to it were added DIEA (450 μL, 2.58 mmol) and dimethylcarbamoyl chloride (240 μL, 2.58 mmol). The mixture was stirred at RT for overnight. It was diluted with 100 mL EtOAc, washed with water ×2, dried, concentrated in vacuo, and subjected to silica flash column using 0 to 3% MeOH in DCM to isolate (4aR,8aR)-5-(6-chloro-5-cyanopyrazin-2-yl)-N,N-dimethyloctahydro-1,5-naphthyridine-1(2H)-carboxamide (424, 56 mg, 19%). It was mixed with 4-(1-cyclopentylpiperidin-4-yl)aniline hydrochloride (304) (90 mg, 0.32 mmol), fine-powder cesium carbonate (210 mg, 0.64 mmol), Pd(OAc)2(11 mg, 0.05 mmol), BINAP (31 mg, 0.05 mmol) in 15 mL dioxane. The mixture was degassed with nitrogen stream for 3 min. It was then stirred in 115° C. bath in nitrogen atmosphere for 1.5 hour. The mixture was cooled to RT, diluted with 100 mL EtOAc, and filtered. The filtrate was concentrated in vacuo and subjected to silica flash column using 0 to 11% MeOH in DCM to isolate (4aR,8aR)-5-(5-cyano-6-(4-(1-cyclopentylpiperidin-4-yl)phenylamino)pyrazin-2-yl)-N,N-dimethyloctahydro-1,5-naphthyridine-1(2H)-carboxamide (425). It was dissolved in 10 mL MeOH and 2 mL DMSO. To it were added one NaOH solid bead (about 100 mg), Et3N (60 μL) and then 0.5 mL 30% H2O2. The mixture was stirred at RT for 30 min, diluted with 10 mL MeCN, stirred for 5 min, and concentrated, acidified with 0.3 mL TFA, and subjected to reverse phase prep HPLC using 5 mM HCl (aq) and neat MeCN as mobile phases to isolate (4aR,8aR)-5-(5-carbamoyl-6-(4-(1-cyclopentylpiperidin-4-yl)phenylamino)pyrazin-2-yl)-N,N-dimethyloctahydro-1,5-naphthyridine-1(2H)-carboxamide (426) as HCl salt (23 mg). LC-MS (ESI): m/z (M+1) 575.8. UV: λ=269, 276, 305, 335, 372 nm.

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS09382246B2
Source datasetuspto-grants-2016_07
ORD IDord-1e1fcd54b1ba4e0b8a923f382afa080f
Source noteuspto-grants-2016_07